一、募集资金基本情况 证券代码：605588 证券简称：冠石科技 公告编号：2025-036 南京冠石科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 中国农业银行股份有限公司 半导体有 39318001040000205 正常使用 经中国证券监督管理委员会《关于核准南京冠石科技股份有限公司首次公开 发行股票的批复》（证监许可〔2021〕2489 号）核准，南京冠石科技股份有限 公司（以下简称"公司"）首次公开发行人民币普通股（A 股）18,275,000 股， 发行价格为 27.42 元/股，募集资金总额为 50,110.05 万元，扣除发行费用 4,523.26 万元后，募集资金净额为 45,586.79 万元。 上述资金已于 2021 年 8 月 5 日全部到位，信永中和会计师事务所（特殊普 通合伙）对上述募集资金到位情况进行了审验，并于 2021 年 8 月 9 日出具了《验 资报告》（XYZH/2021BJAA120480）。公司已与保荐机构、存放募集资金的商 业银行签署了募集资金监管协议，开设了募集 ...

南京冠石科技股份有限公司 关于注销部分募集资金账户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 经中国证券监督管理委员会《关于核准南京冠石科技股份有限公司首次公开 发行股票的批复》（证监许可〔2021〕2489 号）核准，南京冠石科技股份有限 公司（以下简称"公司"）首次公开发行人民币普通股（A 股）18,275,000 股， 发行价格为 27.42 元/股，募集资金总额为 50,110.05 万元，扣除发行费用 4,523.26 万元后，募集资金净额为 45,586.79 万元。 上述资金已于 2021 年 8 月 5 日全部到位，信永中和会计师事务所（特殊普 通合伙）对上述募集资金到位情况进行了审验，并于 2021 年 8 月 9 日出具了《验 资报告》（XYZH/2021BJAA120480）。公司已与保荐机构、存放募集资金的商 业银行签署了募集资金监管协议，开设了募集资金专项账户，对募集资金实行专 户存储。 二、募集资金管理情况 为规范公司募集资金管理，切实保护投资者权益，根据中国证监会 ...

Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]

证券代码：605588 证券简称：冠石科技 公告编号：2025-035 根据《企业会计准则第 16 号——政府补助》的相关规定，上述政府补助均 与收益相关，计入当期损益。具体会计处理及对公司 2025 年度损益的影响最终 以会计师事务所年度审计确认后的结果为准，敬请广大投资者注意投资风险。 特此公告。 南京冠石科技股份有限公司董事会 2025 年 7 月 2 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、获得补助的基本情况 2025 年 6 月 30 日，南京冠石科技股份有限公司（以下简称"公司"）全资 子公司宁波冠石半导体有限公司获得与收益相关的政府补助 700 万元，占公司 2024 年度归属于上市公司股东净利润绝对值的比例为 45.29%。 二、补助的类型及其对上市公司的影响 南京冠石科技股份有限公司 关于获得政府补助的公告 ...

Core Insights - The polarized lens industry is experiencing significant growth driven by the rapid development of the consumer electronics sector, particularly in smartphones, tablets, and laptops, leading to increased demand for polarized lenses [1][11] - Government support for new materials industries, as outlined in the "Industrial Strategic Emerging Industries Classification Directory (2023)," is further propelling the development of the polarized lens industry [1][11] - The market size of the polarized lens industry has risen from 14.74 billion yuan in 2018 to 31 billion yuan, with expectations for continued growth as downstream application areas expand [1][11] Industry Overview - Polarized lenses, also known as polarizing filters, are used to eliminate direct light and enhance visual clarity, making them essential in various applications including eyewear, camera lenses, and LCD displays [3][11] - The industry has evolved through three stages: a nascent phase from 1995-1999, a startup phase from 2000-2010, and a high-growth phase from 2011 to present, with significant advancements in technology and market competitiveness [5][11] Industry Chain - The polarized lens industry chain consists of upstream raw materials (polarizing films, protective films, adhesive materials), midstream manufacturers who produce the final products, and downstream applications in eyewear, cameras, and electronic devices [7][11] Competitive Landscape - Domestic companies are enhancing their market competitiveness through technological innovation and industrial upgrades, although there remains a gap in high-end products compared to international leaders [13] - Key players in the industry include Ningbo Shanshan Co., Ltd., Hengmei Optoelectronics Co., Ltd., and Shenzhen Sanlipu Optoelectronics Co., Ltd., among others [13][15] Market Trends - The demand for polarized lenses is expected to grow as consumers increasingly prioritize health, safety, and fashion, with applications expanding into emerging fields like virtual reality and autonomous driving [21][22] - International demand for Chinese polarized lens products is rising, supported by the increasing recognition and competitiveness of Chinese brands in global markets [22] - Market concentration is anticipated to increase as leading companies expand production capacities, with Hengmei Optoelectronics planning to add 140 million square meters of polarized lens capacity by 2027 [24]

证券代码：605588 证券简称：冠石科技 公告编号：2025-034 南京冠石科技股份有限公司关于使用部分闲置 募集资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司使用部分闲置募集资金进行现金管理时，将选择安全性高、流动性好的 保本型产品。但金融市场受宏观经济的影响较大，不排除该项投资受到政策风险、 市场风险、信用风险、流动性风险、信息传递风险、不可抗力风险等因素影响， 导致收益波动。公司将根据经济形势以及金融市场的变化适时适量地介入，敬请 广大投资者注意投资风险。 一、本次现金管理概况 现金管理受托方：中国农业银行股份有限公司 现金管理金额：人民币5,000万元 现金管理产品名称及产品期限："汇利丰"2025年第5659期对公定制人 民币结构性存款产品，产品期限28天。 履行的审议程序： （一）现金管理目的 为提高募集资金使用效率和收益，合理利用闲置募集资金，在保证不影响募 集资金投资项目正常实施和确保募集资金安全的前提下，公司拟利用部分闲置募 集资金进行现金管理，增加公司现 ...

证券代码：605588 证券简称：冠石科技 公告编号：2025-033 南京冠石科技股份有限公司 关于签订募集资金四方监管协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 经中国证券监督管理委员会《关于核准南京冠石科技股份有限公司首次公开 发行股票的批复》（证监许可〔2021〕2489 号）核准，南京冠石科技股份有限 公司（以下简称"公司"）首次公开发行人民币普通股（A 股）18,275,000 股， 发行价格为 27.42 元/股，募集资金总额为 50,110.05 万元，扣除发行费用 4,523.26 万元后，募集资金净额为 45,586.79 万元。 甲方一：南京冠石科技股份有限公司 甲方二：宁波冠石半导体有限公司 （"甲方一"与"甲方二"合称为"甲方"） 上述资金已于 2021 年 8 月 5 日全部到位，信永中和会计师事务所（特殊普 通合伙）对上述募集资金到位情况进行了审验，并于 2021 年 8 月 9 日出具了《验 资报告》（XYZH/2021BJAA120480）。公司已与保荐机 ...

? 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 05 月 13 日 (二)股东大会召开的地点：南京经济技术开发区新港大道 88 号南京翠屏新港假 日酒店 4 楼 VIP1 会议厅 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：605588 证券简称：冠石科技 公告编号：2025-032 南京冠石科技股份有限公司 二、 议案审议情况 (一)非累积投票议案 审议结果：通过 表决情况： | 股东类型 | | 同意 | | 反对 | | 弃权 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 票数 | | 比例 | | | | | | | | | （%） | 票数 | | 比例 | 票数 | 比例 | | | | | | （%） | | （%） | | | A股 | 49,699,534 | 99.9467 | 12,100 | 0.0243 | 14,400 | 0.0290 | | | 审议结 ...

北京市金杜（南京）律师事务所 关于南京冠石科技股份有限公司 2024 年年度股东大会 之法律意见书 致：南京冠石科技股份有限公司 北京市金杜（南京）律师事务所（以下简称本所）接受南京冠石科技股份 有限公司（以下简称公司）委托，根据《中华人民共和国证券法》《中华人民 共和国公司法》、中国证券监督管理委员会（以下简称中国证监会）《上市公 司股东会规则》（以下简称《股东会规则》）等中华人民共和国境内（以下简 称中国境内，为本法律意见书之目的，不包括中华人民共和国香港特别行政区、 中华人民共和国澳门特别行政区和中华人民共和国台湾地区）现行有效的法律、 行政法规、规章及规范性文件和现行有效的公司章程有关规定，指派律师出席 了公司于 2025 年 5 月 13 日召开的 2024 年年度股东大会（以下简称本次股东 大会），并就本次股东大会相关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限 于： 章程》（以下简称《公司章程》）； （http://www.sse.com.cn）及《上海证券报》《证券时报》的《南京冠 石科技股份有限公司第二届董事会第二十四次会议决议公告》及《南京 冠石 ...

证券代码：605588 证券简称：冠石科技 公告编号：2025-032 南京冠石科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 05 月 13 日 (二)股东大会召开的地点：南京经济技术开发区新港大道 88 号南京翠屏新港假 日酒店 4 楼 VIP1 会议厅 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 126 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 49,726,034 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 67.6705 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，采取现场和网络投票相结合的方式召开， 由董事长张建巍先生主持。本次股东大 ...